Physician profile
Amanda D Denham
NPI 1245433648
$45,190.13
in general payments reported to CMS, 2019-2025
23 companies · $4,758 in 2025
The $4,758 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $6,541 · 2021: $14K · 2022: $13K · 2023: $4,759 · 2024: $242 · 2025: $4,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,216 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Food and Beverage: $1,542 · Travel and Lodging: $217 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,216.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Food and Beverage | $1,541.65 |
| Travel and Lodging | $217.00 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35,698.04 | 2019-2024 | Breztri, Airsupra, Symbicort |
| Genzyme Corporation | $5,075.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,541.33 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $539.90 | 2021-2024 | Dupixent |
| Grifols USA, LLC | $519.91 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.39 | 2019-2023 | Ofev |
| Genentech USA, INC. | $231.00 | 2019-2022 | |
| Mylan Specialty L.P. | $173.75 | 2019-2023 | Yupelri |
| Baxter Healthcare | $164.36 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $150.47 | 2019-2022 | |
| Amgen INC. | $141.96 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $102.91 | 2020-2022 | |
| Harmony Biosciences LLC | $90.15 | 2020-2022 | |
| Philips North America LLC | $69.94 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.78 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $61.70 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $31.81 | 2019 | |
| Inogen, INC. | $25.99 | 2022 | |
| Shire North American Group INC | $20.37 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.88 | 2021 | |
| Pulmonx Corporation | $13.51 | 2022 | |
| Optinose US, INC. | $13.24 | 2019 | |
| Merck Sharp & Dohme LLC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Denham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.